The Classical Apoptotic Adaptor FADD Regulates Glycolytic Capacity in Acute Lymphoblastic Leukemia.


Journal

International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568

Informations de publication

Date de publication:
2022
Historique:
received: 13 10 2021
accepted: 07 03 2022
entrez: 31 5 2022
pubmed: 1 6 2022
medline: 3 6 2022
Statut: epublish

Résumé

The Fas-associated death domain (FADD) has long been regarded as a crucial adaptor protein in the extrinsic apoptotic pathway. Despite the non-apoptotic function of FADD is gradually being discovered and confirmed, its corresponding physiological and pathological significance is still unclear. Based on the database of GWAS catalog and GTEx Portal, 17 SNPs associated with leukemia susceptibility were found to be linked to FADD expression. We then investigated a regulatory role of FADD in T-acute lymphoblastic leukemia (T-ALL) using Jurkat cells as a model. Jurkat cells stably depleted of FADD (FADD

Identifiants

pubmed: 35637951
doi: 10.7150/ijbs.68016
pii: ijbsv18p3137
pmc: PMC9134909
doi:

Substances chimiques

FADD protein, human 0
Fas-Associated Death Domain Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3137-3155

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

EMBO Mol Med. 2016 Aug 01;8(8):895-918
pubmed: 27357657
Mitochondrion. 2016 Sep;30:222-8
pubmed: 27544294
Medicine (Baltimore). 2016 May;95(18):e3542
pubmed: 27149463
Mol Cells. 2020 Apr 30;43(4):373-383
pubmed: 32191993
Nature. 2011 Mar 17;471(7338):373-6
pubmed: 21368761
Science. 2010 Dec 3;330(6009):1340-4
pubmed: 21127244
Oncogene. 2011 Jan 27;30(4):471-81
pubmed: 20890306
Nat Commun. 2013;4:2935
pubmed: 24343302
Oncotarget. 2018 May 1;9(33):22907-22914
pubmed: 29796161
J Proteome Res. 2008 Jan;7(1):254-65
pubmed: 18159924
Mol Cell Biol. 2010 Dec;30(24):5698-709
pubmed: 20937774
Nat Commun. 2014;5:3351
pubmed: 24548998
J Pineal Res. 2017 Aug;63(1):
pubmed: 28398674
Hum Pathol. 2011 Aug;42(8):1117-24
pubmed: 21315423
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2011 Dec 1;71(23):7207-15
pubmed: 21978935
Cancer Res. 2013 Mar 1;73(5):1524-35
pubmed: 23288510
J Clin Oncol. 2007 Sep 20;25(27):4262-9
pubmed: 17724347
Nature. 2008 Mar 13;452(7184):230-3
pubmed: 18337823
J Biol Chem. 2000 Aug 18;275(33):25065-8
pubmed: 10862756
Biochem J. 2005 Feb 15;386(Pt 1):73-83
pubmed: 15456403
Immunity. 2003 Apr;18(4):513-21
pubmed: 12705854
Carcinogenesis. 2019 Oct 16;40(10):1260-1268
pubmed: 30805584
Biochim Biophys Acta. 2007 Aug;1773(8):1256-62
pubmed: 17442414
Cancer Biol Ther. 2006 Nov;5(11):1523-9
pubmed: 17012850
Biochem Soc Symp. 1999;66:17-25
pubmed: 10989653
J Exp Med. 2000 Oct 16;192(8):1165-74
pubmed: 11034606
J Biol Chem. 2020 Oct 9;295(41):14214-14221
pubmed: 32796034
J Chromatogr A. 2008 Oct 24;1208(1-2):175-81
pubmed: 18790488
Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
pubmed: 18097445
Curr Opin Struct Biol. 2011 Aug;21(4):532-40
pubmed: 21831629
Cell. 2012 Mar 16;148(6):1145-59
pubmed: 22424226
Mol Cell. 2005 Aug 5;19(3):321-32
pubmed: 16061179
Blood. 2001 Dec 15;98(13):3770-7
pubmed: 11739185
Cell Metab. 2018 Dec 4;28(6):848-865.e6
pubmed: 30174307
Cancer Lett. 2015 Jan 28;356(2 Pt A):156-64
pubmed: 24732809
Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15
pubmed: 25241037
Sci Signal. 2015 Jan 27;8(361):ra9
pubmed: 25628462
J Biol Chem. 2007 Aug 3;282(31):22786-92
pubmed: 17553783
Cancer Cell. 2006 Jun;9(6):425-34
pubmed: 16766262

Auteurs

Wenzhao Zhou (W)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Yueyang Lai (Y)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Jianhui Zhu (J)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Xuebo Xu (X)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Wenliang Yu (W)

School of Biopharmacy, China Pharmaceutical University, Nanjing, China.
Changzhou High-Tech Research Institute of Nanjing University and Jiangsu Target Pharma Laboratories Inc., Changzhou, China.

Zengzheng Du (Z)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Leyang Wu (L)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Xuerui Zhang (X)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
Changzhou High-Tech Research Institute of Nanjing University and Jiangsu Target Pharma Laboratories Inc., Changzhou, China.

Zichun Hua (Z)

The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
School of Biopharmacy, China Pharmaceutical University, Nanjing, China.
Changzhou High-Tech Research Institute of Nanjing University and Jiangsu Target Pharma Laboratories Inc., Changzhou, China.
Shenzhen Research Institute of Nanjing University, Shenzhen, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH